Samjin Pharmaceuticals Co., Ltd. (KRX:005500)

South Korea flag South Korea · Delayed Price · Currency is KRW
19,150
+90 (0.47%)
Apr 28, 2026, 3:30 PM KST
7.52%
Market Cap 234.74B
Revenue (ttm) 274.03B
Net Income (ttm) 21.89B
Shares Out 12.26M
EPS (ttm) 1,727.82
PE Ratio 11.08
Forward PE 11.51
Dividend 800.00 (4.20%)
Ex-Dividend Date Dec 29, 2025
Volume 31,590
Average Volume 19,066
Open 19,310
Previous Close 19,060
Day's Range 19,120 - 19,460
52-Week Range 16,990 - 21,300
Beta 0.16
RSI 60.88
Earnings Date Feb 3, 2026

About Samjin Pharmaceuticals

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clin... [Read more]

Sector Healthcare
Founded 1968
Employees 586
Stock Exchange Korea Stock Exchange
Ticker Symbol 005500
Full Company Profile

Financial Performance

In 2022, Samjin Pharmaceuticals's revenue was 274.03 billion, an increase of 9.58% compared to the previous year's 250.07 billion. Earnings were 21.89 billion, a decrease of -22.92%.

Financial Statements

News

There is no news available yet.